Ultragenyx's Emil Kakkis on this week's Angelman syndrome data, rare disease treatment modalities, and more
Emil Kakkis summarizes Ultragenyx's Angelman syndrome update at AAN, discusses use cases for various treatment modalities, and gives his take on the current state of rare disease drug development.